CN106999573B - 佐剂组合物 - Google Patents

佐剂组合物 Download PDF

Info

Publication number
CN106999573B
CN106999573B CN201580065778.3A CN201580065778A CN106999573B CN 106999573 B CN106999573 B CN 106999573B CN 201580065778 A CN201580065778 A CN 201580065778A CN 106999573 B CN106999573 B CN 106999573B
Authority
CN
China
Prior art keywords
nucleic acid
rna
stranded nucleic
cancer
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580065778.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106999573A (zh
Inventor
濑谷司
松本美佐子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Immunotherapy Institute
Original Assignee
Advanced Immunotherapy Institute
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Immunotherapy Institute, Hokkaido University NUC filed Critical Advanced Immunotherapy Institute
Publication of CN106999573A publication Critical patent/CN106999573A/zh
Application granted granted Critical
Publication of CN106999573B publication Critical patent/CN106999573B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580065778.3A 2014-12-02 2015-12-01 佐剂组合物 Active CN106999573B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-244421 2014-12-02
JP2014244421A JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物
PCT/JP2015/083825 WO2016088784A1 (ja) 2014-12-02 2015-12-01 アジュバント組成物

Publications (2)

Publication Number Publication Date
CN106999573A CN106999573A (zh) 2017-08-01
CN106999573B true CN106999573B (zh) 2021-10-19

Family

ID=56091725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580065778.3A Active CN106999573B (zh) 2014-12-02 2015-12-01 佐剂组合物

Country Status (7)

Country Link
US (1) US10105385B1 (enExample)
EP (1) EP3228322B8 (enExample)
JP (1) JP6453063B2 (enExample)
CN (1) CN106999573B (enExample)
AU (1) AU2015356078B2 (enExample)
CA (1) CA2969024C (enExample)
WO (1) WO2016088784A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020473B2 (en) * 2016-06-24 2021-06-01 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
WO2018021400A1 (ja) 2016-07-27 2018-02-01 国立大学法人北海道大学 がん免疫アジュバント
JP7219212B2 (ja) * 2016-09-06 2023-02-07 エフ．ホフマン－ラ ロシュ アーゲー Ｍｈｃ結合ペプチドアレイおよびその使用方法
JPWO2024122480A1 (enExample) 2022-12-05 2024-06-13

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294628A (zh) * 1998-03-26 2001-05-09 美国氰胺公司 引起麻疹病毒或人呼吸道合胞病毒亚组b减毒的突变
CN102000330A (zh) * 2010-09-14 2011-04-06 中国人民解放军第二军医大学 一种核酸疫苗佐剂及其构建方法
CN103003427A (zh) * 2010-07-28 2013-03-27 国立大学法人北海道大学 具有佐剂活性的新型核酸及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008065752A1 (ja) * 2006-11-30 2010-03-04 国立大学法人北海道大学 ｄｉＲＮＡを有効成分とする免疫治療用薬剤
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294628A (zh) * 1998-03-26 2001-05-09 美国氰胺公司 引起麻疹病毒或人呼吸道合胞病毒亚组b减毒的突变
CN103003427A (zh) * 2010-07-28 2013-03-27 国立大学法人北海道大学 具有佐剂活性的新型核酸及其应用
CN102000330A (zh) * 2010-09-14 2011-04-06 中国人民解放军第二军医大学 一种核酸疫苗佐剂及其构建方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"保护性特异性抗肿瘤免疫核糖核酸纳米粒制备及质量评价";张红菱等;《中国医院药学杂志》;20070218;第27卷(第2期);第199-201页 *
《DNA疫苗免疫佐剂研究进展》;尹荣兰等;《中国兽医杂志》;20080422;第44卷(第4期);第77-79页 *

Also Published As

Publication number Publication date
AU2015356078B2 (en) 2021-09-16
WO2016088784A1 (ja) 2016-06-09
EP3228322B8 (en) 2019-06-19
EP3228322A1 (en) 2017-10-11
CA2969024C (en) 2022-05-24
AU2015356078A1 (en) 2017-06-29
EP3228322A4 (en) 2018-05-30
US10105385B1 (en) 2018-10-23
EP3228322B1 (en) 2019-04-10
JP2016108250A (ja) 2016-06-20
JP6453063B2 (ja) 2019-01-16
US20180280425A1 (en) 2018-10-04
CN106999573A (zh) 2017-08-01
CA2969024A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
KR102623786B1 (ko) 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
EP2599866B1 (en) Novel nucleic acid having adjuvant activity and use thereof
EP3010514B1 (en) Double-stranded antisense nucleic acid with exon-skipping effect
JP2021512090A (ja) 免疫細胞に薬剤を送達するための組成物及び方法
KR102825946B1 (ko) IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
KR20190020299A (ko) 면역 조정 폴리펩타이드를 암호화하는 mRNA의 조합물 및 이의 용도
CN116785445B (zh) 靶向化学药物及其制备方法、药物组合物、靶向化学药物的应用
CN106999573B (zh) 佐剂组合物
JP7306653B2 (ja) 構造強化されたＳ－ＴｕＤを用いた新規がん治療法
JP2025105923A (ja) 胃癌分子標的核酸医薬
JP7642824B2 (ja) 遺伝子発現および抑制が同時に可能な核酸構造体
WO2024081970A2 (en) Novel antisense oligonucleotides containing hybrid morpholino and dna/rna(modified) with phosphorothioate (ps) linker for the treatment of cancer and autoimmune disorders
US11298371B2 (en) Regulation of nucleic acid molecule expression
JP2025534021A (ja) 修飾オリゴヌクレオチド
WO2025080939A1 (en) Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190613

Address after: Tokyo, Japan, Japan

Applicant after: Future Medical Innovation and Development of the Company

Address before: Hokkaido Japan

Applicant before: National University Corporation Hokkaido University

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210929

Address after: Aomori Japan

Applicant after: Advanced immunotherapy Institute

Address before: Tokyo, Japan

Applicant before: Future Medical Innovation Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant